• 1
    Valdes LJ III, Diaz JL, Paul AG. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J Ethnopharmacol 1983; 7: 287312.
  • 2
    Siebert DJ. Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum. Ann Bot 2004; 93: 76371.
  • 3
    Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 2004; 102: 1318.
  • 4
    Valdes LJ, III, Hatfield GM, Koreeda M, Paul AG. Studies of Salvia divinorum (Lamiaceae), an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico. Econ Bot 1987; 41; 28391.
  • 5
    Halpern JH, Pope HG Jr. Hallucinogens on the Internet: a vast new source of underground drug information. Am J Psychiatry 2001; 158: 4813.
  • 6
    Valdes LJ, III. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs 1994; 26: 27783.
  • 7
    Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 1994; 43: 5356.
  • 8
    Sheffler DJ, Roth BL. Salvinorin A: the ‘‘magic mint“ hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003; 24: 1079.
  • 9
    Halpern JH. Hallucinogens: an update. Curr Psychiatry Rep 2003; 5: 34754.
  • 10
    Roth BL, Baner K, Westkaemper R et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002; 99: 119349.
  • 11
    Chavkin C, Sud S, Jin W et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004; 308: 1197203.
  • 12
    Wang Y, Tang K, Inan S et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005; 312: 22030.
  • 13
    Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem 2005; 48: 3458.
  • 14
    Waterman SA, Costa M, Tonini M. Modulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioids. Br J Pharmacol 1992; 106: 100410.
  • 15
    Shahbazian A, Heinemann A, Schmidhammer H, Beubler E, Holzer-Petsche U, Holzer P. Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br J Pharmacol 2002; 135: 74150.
  • 16
    Izzo AA, Costa M, Mascolo N, Capasso F. The role of histamine H1, H2 and H3 receptors on enteric ascending synaptic transmission in the guinea pig ileum. J Pharmacol Exp Ther 1998; 287: 9527.
  • 17
    Storr M, Hahn A, Gaffal E, Saur D, Allescher HD. Effects of endomorphin-1 and -2 on mu-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. Clin Exp Pharmacol Physiol 2002; 29: 42834.
  • 18
    Nocerino E, Izzo AA, Borrelli F et al. Relaxant effect of capsazepine in the isolated rat ileum. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 18792.
  • 19
    Wasson RG. A new Mexican psychotropic drug from the mint family. Bot Mus Leafl 1962; 20: 7784.
  • 20
    Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 1728.
  • 21
    Burks TF. Opioid peptides in gastrointestinal function. In: TsengLF, ed. The Pharmacology of Opioid Peptides. Australia: Harwood Academy Publishers, 1995: 397409.
  • 22
    Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 316.
  • 23
    Crist JR, He XD, Goyal RK. Both ATP and the peptide VIP are inhibitory neurotransmitters in guinea-pig ileum circular muscle. J Physiol 1992; 447: 11931.
  • 24
    Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984; 35: 250511.
  • 25
    Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 1998; 79: 23157.
  • 26
    Kojima Y, Takahashi T, Fujina M, Owyang C. Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J Pharmacol Exp Ther 1994; 268: 96570.
  • 27
    Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 2004; 172: 2204.
  • 28
    Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 2005; 179: 5518.